Pharmacological treatment of binge eating disorder: Update review and synthesis

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 10, 2015, Pages 1463-1478

  Reas, Deborah L ^a   Grilo, Carlos M ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Binge eating; Binge eating disorder; Medication; Obesity; Pharmacotherapy; Placebo

Indexed keywords

ACAMPROSATE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; CENTRAL STIMULANT AGENT; SAMIDORPHAN; FRUCTOSE; TOPIRAMATE;

ABSTINENCE; BINGE EATING DISORDER; BODY MASS; COGNITIVE THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BINGE-EATING DISORDER; BODY WEIGHT; DRUG EFFECTS; OBESITY;

ANTI-OBESITY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BINGE-EATING DISORDER; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; FRUCTOSE; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84933520082     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1053465     Document Type: Review

References (43)

1. APA. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. American Psychiatric Publishing; Arlington, VA: 2013
2. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348-58
3. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization world mental health surveys. Biol Psychiatry 2013; 73: 904-14
4. Marques L, Alegria M, Becker AE, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: Implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord 2011; 44: 412-20
5. Allison KC, Grilo CM, Masheb RM, Stunkard AJ. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol 2005; 73: 1107-15
6. Grilo CM, Crosby RD, Masheb RM, et al. Overvaluation of shape and weight in binge eating disorder, bulimia nervosa, and sub-Threshold bulimia nervosa. Behav Res Ther 2009; 47: 692-6
7. Grilo CM, Hrabosky JI, White MA, et al. Overvaluation of shape and weight in binge eating disorder and overweight controls: refinement of a diagnostic construct. J Abnorm Psychol 2008; 117: 414-19
8. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association; Washington, DC: 1994
9. Reas DL, Grilo CM. Review and metaanalysis of pharmacotherapy for bingeeating disorder. Obesity 2008; 16: 2024-38
10. Ivezaj V, Kalebjian R, Grilo CM, Barnes RD. Comparing weight gain in the year prior to treatment for overweight and obese patients with and without binge eating disorder in primary care. J Psychosom Res 2014; 77: 151-4
11. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebocontrolled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry 1992; 49: 139-47
12. Arnold LM, McElroy SL, Hudson JI, et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002; 63: 1028-33
13. Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005; 13: 1077-88
14. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized doubleblind placebo-controlled comparison. Biol Psychiatry 2005; 57: 301-9
15. Leombruni P, Piero A, Lavagnino L, et al. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1599-605
16. Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a oneyear follow-up study. Psychother Psychosom 2001; 70: 298-3064
17. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial.102 Am J Psychiatry 1998; 155: 1756-62
18. Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol 2008; 23: 1-11
19. Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord 2012; 45: 281-9
20. Grilo CM, Crosby RD, Wilson GT, Masheb RM. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol 2012; 80: 1108-13
21. Devlin MJ, Goldfein JA, Petkova E, et al. Cognitives behavioral therapy and fluoxetine for binge eating disorder: twoyear follow-up. Obesity 2007; 15: 1702-9
22. White MA, Grilo CM. Buproprion for overweight women with binge eating disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74: 400-6
23. Agras WS, Telch CF, Arnow B. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder: An additive design. Behav Ther 1994; 25: 225-38
24. Claudino AM, De Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior Pharmacological treatment of binge eating disorder therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 1324-32
25. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-61
26. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61: 1039-48
27. Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009; 24: 150-8
28. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1897-906
29. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-Term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004; 65: 1463-9
30. Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005; 13: 1701-8
31. Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided selfhelp and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2005; 57: 1193-201
32. Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther 2013; 51: 167-75
33. McElroy SL, Guerdjikova AI, Winstanley EL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011; 44: 81-90
34. McElroy SL, Guerdjikova AI, Blom TJ, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord 2013; 46: 239-45
35. McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390-8
36. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72: 235-46
37. Citrome L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 2015; 69(4): 410-21
38. McElroy SL, Hudson JI, Ferreira-Cornwell C, et al. Randomized controlled safety and efficacy trials of lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder. American Psychiatric Association 167th Annual Meeting; May 3-7, 2014; New York, NY
39. Grilo CM, Masheb RM, White MA, et al. Treatment of binge eating in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinincal trial of selfhelp and medication. Behav Res Ther 2013; 51: 855-61
40. Grilo CM, Masheb RM, Crosby RD. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. J Consult Clin Psychol 2012; 80: 897-906
41. Thompson-Brenner H, Franko DL, Thompson DR, et al. Race/ethnicity, education, and treatment parameters as moderators and predictors of outcome in binge eating disorder. J Consult Clin Psychol 2013; 81: 710-21
42. Grilo CM, Masheb RM, Wilson GT. Rapid response to treatment for binge eating disorder. J Consult Clin Psychol 2006; 74: 602-13
43. Grilo CM, White MA, Masheb RM, Gueorguieva R. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: the significance of early rapid response. J Consult Clin Psychol 2015; 83: 387-94